Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGeneral Clinical Specialties

Predictive factors of repeat therapy in patients receiving iodine-131 for Graves’ disease

Ruiguo Zhang, Lan Qin, Zhong Ren and Junqi Wang
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 36;
Ruiguo Zhang
1Department of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lan Qin
1Department of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhong Ren
1Department of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junqi Wang
1Department of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

36

Objectives To explore the factors predicting repeat 131I therapy in patients with Graves' disease (GD).

Methods We collected clinical data on 1707 patients with GD (1174 females and 533 males, mean age 40.4±12.2 yrs) presenting consecutively between Jan 2002 and Nov 2010 who were treated with 131I. 131I dose (MBq)= 131I dose for per gram of thyroid tissue (MBq/g) × thyroid weight (g) / 24h radioactive iodine uptake (24h-RAIU). The influence of factors including patient’s gender, age, course of hyperthyroidism (mons), whether taking ATD before 131I therapy, thyroid weight(g), the texture(soft, moderate or stiff), with complications or not, 24h-RAIU(%), whether peak RAIU moving forward or not, the first dose of 131I and giving 131I dose per gram thyroid tissue was determined. Logistic Regression was used to determine which factors contributed to the prediction of repeat 131I therapy.

Results Overall, 1540 patients (90.2%) received a single dose of 131I. The remaining 167 cases were given a further dose of 131I (range: 2-4 doses). In the univariate analysis, subjects receiving more than one dose of 131I had a longer course of hyperthyroidism, heavier weight, higher 24h-RAIU, larger initial 131I dose and 131I dose per gram thyroid tissue when compared with those underwent a single dose, and patients taking ATD before 131I therapy and those whose peak RAIU moving forward were more likely retreated (P<0.05). Multivariate logistic regression analysis identified longer course of hyperthyroidism (OR:1.004, 95%CI:1.001-1.007, P=0.01), heavier weight (OR:1.011,95%CI:1.005-1.016, P<0.001) and peak RAIU moving forward (OR:1.787, 95%CI:1.183-2.697, P=0.006) to be independent factors predicting repeat treatment.

Conclusions A single dose 131I therapy for the majority of GD patients can exert good therapeutic effects. Subjects with longer course of hyperthyroidism, heavier weight and peak RAIU moving forward should be treated with a relatively high dose of 131I in order to achieve cure.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 54, Issue supplement 2
May 2013
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predictive factors of repeat therapy in patients receiving iodine-131 for Graves’ disease
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Predictive factors of repeat therapy in patients receiving iodine-131 for Graves’ disease
Ruiguo Zhang, Lan Qin, Zhong Ren, Junqi Wang
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 36;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Predictive factors of repeat therapy in patients receiving iodine-131 for Graves’ disease
Ruiguo Zhang, Lan Qin, Zhong Ren, Junqi Wang
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 36;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

General Clinical Specialties

  • 18F-FDG PET/CT Imaging of Infection and Inflammation
  • Association between diffuse F18-FDG thyroid uptake and thyroid dysfunction
  • Bone Scintigraphy in Complex Regional Pain Syndrome Type I: A Pictorial Review
Show more General Clinical Specialties

Endo I: Benign Thyroid Diseases

  • The long term effects of radio-iodine therapy versus antithyroid medications on Graves' disease
  • Does low iodine diet improve radioiodine uptake in hyperthyroidism?
Show more Endo I: Benign Thyroid Diseases

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire